Stockreport

Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

Bristol-Myers Squibb Company  (BMY) 
Last bristol-myers squibb company earnings: 2/6 07:05 am Check Earnings Report
US:NYSE Investor Relations: bms.com/investors.html
PDF 95.7% of patients responded to Breyanzi in the TRANSCEND FL trialBreyanzi provided sustained clinical benefit with median duration of response not reached and the majori [Read more]